The neuropeptide bradykinin (BK) sensitizes nociceptor activation following its release in response to inflammatory injury. Thereafter, the bioactivity of bradykinin is controlled by the enzymatic activities of circulating peptidases. One such enzyme, the metalloendopeptidase EC3.4.24.15 (EP24.15), is co-expressed with bradykinin receptors in primary afferent neurons. In this study, using approaches encompassing pharmacology, biochemistry, cell biology, and behavioral animal models, we identified a crucial role for EP24.15 and the closely related EP24.16 in modulating bradykinin-mediated hyperalgesia. Pharmacological analyses indicated that EP24.15 and EP24.16 inhibition significantly enhances bradykinin type-2 receptor activation by bradykinin in primary trigeminal ganglia cultures. In addition, bradykinin-induced sensitization of TRPV1 activation was increased in the presence of the EP24.15/16 inhibitor JA-2. Furthermore, behavioral analyses illustrated a significant dose-response relationship between JA-2 and bradykinin-mediated thermal hyperalgesia. These results indicate an important physiological role for the metallopeptidases EP24.15 and EP24.16 in regulating bradykinin-mediated sensitization of primary afferent nociceptors. Ó
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Introduction
Bradykinin (BK) is a potent neuropeptide that stimulates numerous physiological processes through the activation of the constitutively expressed bradykinin type-2 receptor (B2R) of the rhodopsin G-protein-coupled receptor (GPCR) class [19] . The type-1 receptor subtype (B1R) is poorly expressed in normal (non-nflamed) tissue and is activated by metabolic products of bradykinin, including des-Arg 9 -BK. However, B1R expression increases incrementally after inflammation [23] . After exposure to full-length BK, B2R activation mediates important physiologic functions, including blood pressure regulation, smooth muscle contraction, and pain [19] . The predominance of these functions follow the activation of B2R-driven Gaq-signaling pathways, that increase the downstream activities of many molecules, including protein kinase C, phospholipase Cb, ras, and MAPK [3] . B2R-mediated activation of PKC directs the sensitization and/or activation of various nociceptive receptor-channels, including TRPV1 and TRPA1 [1,10].
The neuropeptide BK is sensitive to extracellular degradation by both circulating and plasma membrane-bound peptidases. Although degradation produces bioactive agonists for B1R, it significantly reduces agonist availability for B2R activation. 
